Abstract

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma

Highlights

  • Multiple myeloma (MM) is a heterogeneous disease in the context of treatment outcomes depending on the presence or absence of the disease-related risk factors including stage and chromosomal abnormality, patient-related factors including age and comorbidity and treatment-related factors including the use of novel agents and/or autologous stem cell transplantation (ASCT).[1]

  • Clinical trials of novel agents comprising thalidomide, lenalidomide and bortezomib have shown a significant improvement in progression-free survival and overall survival (OS) in both transplant-eligible and ineligible patients.[4,5]

  • The Japanese Society of Myeloma surveyed the clinical features of 1383 patients diagnosed and treated between January 1990 and December 2000.11 At that time, neither proteasome inhibitors nor immunomodulatory drugs were available for the routine practice in Japan, and most patients were treated with conventional chemotherapy alone and the remaining patients were treated with ASCT after induction with conventional chemotherapeutic agents

Read more

Summary

Introduction

Multiple myeloma (MM) is a heterogeneous disease in the context of treatment outcomes depending on the presence or absence of the disease-related risk factors including stage and chromosomal abnormality, patient-related factors including age and comorbidity and treatment-related factors including the use of novel agents and/or autologous stem cell transplantation (ASCT).[1]. The diagnosis of MM was made according to the International Myeloma Working Group criteria and the clinical stage was determined based on the Durie & Salmon staging system (D&S) and/or the International Staging System (ISS).[12,13] Response to treatment was assessed according to the international uniform criteria.[14] Fisher’s exact test was used to compare differences between numerical values and the Cohort cohort (n = 1208)

Results
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.